BiotechTube
Nano Pharmasolutions

Nano Pharmasolutions

San Diego, United States· Est.
nanopharmasolutions.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Nano PharmaSolutions is a private, clinical-stage biotech leveraging its proprietary NanoTransformer® platform to reformulate drugs with poor solubility. The company's lead program, NT-301, is in Phase 1 trials and represents its strategic pivot towards CNS disorders via its Nano-CNS® nasal powder delivery platform. With a key manufacturing partnership with Mikart and a pipeline targeting Parkinson's disease and other neurological conditions, NPS is positioning itself in the high-value nanomedicine and CNS drug delivery space. The company appears to be pre-revenue, advancing its programs through partnerships and investor funding.

Central Nervous System (CNS)Neurology

Technology Platform

NanoTransformer®: A patented nanodrug manufacturing platform that improves drug solubility and bioavailability without using lipids, polymers, or solvents. Its specialized application is Nano-CNS®, a nose-to-brain delivery system formulating drugs as a dry powder for nasal administration.

Opportunities

The large and growing market for CNS disorders, coupled with the significant unmet need for non-invasive, fast-acting therapies, presents a major opportunity.
The company's platform technology also addresses the pervasive challenge of poor drug solubility across the pharmaceutical industry, enabling potential future partnerships or application to other therapeutic areas.

Risk Factors

Key risks include the inherent uncertainty of clinical development, particularly for novel delivery routes like nose-to-brain.
As a pre-revenue private company, it faces funding and dilution risks.
The competitive landscape for both solubility enhancement and CNS drug delivery is intense, requiring strong IP protection.

Competitive Landscape

NPS competes in the crowded nanotechnology drug delivery space, which includes companies like Alkermes, Pacira, and numerous startups. Its specific focus on solvent/polymer-free formulation and nasal CNS delivery differentiates it. However, it faces competition from other nose-to-brain delivery specialists and large pharma companies developing intranasal neurotherapeutics.

More companies in Drug Delivery & Formulation →More companies in United States →